Biogen's Busy Pipeline: Continued Confusion On BAN2401, But Other Irons In The Fire
Company highlighted recent pipeline advances in a variety of neuroscience indications during its third-quarter earnings report.
You may also be interested in...
Biogen To Launch Phase III Alzheimer’s Prevention Study
The firm announced plans to begin a Phase III study of aducanumab to prevent or delay the onset of Alzheimer’s, but refused to discuss ongoing studies during its fourth quarter earnings call.
Clinical Trials In Review: Big Hits And Misses In 2018
Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.
United Neuroscience To Move Forward Alzheimer's Vaccine After Promising Phase IIa
It's early days yet and Alzheimer's is a field littered with failures, but the latest results for the vaccine UB-311 support advancing development.